Clinical trial Recruiting at 1 site Interventional Ages 18 to 70

Self-guided ACT-based app for fibromyalgia management

Official title: Three-arm Randomized Controlled Trial Investigating the Effectiveness, Cost-utility, and Physiological Effects of the Spanish Version of STANZA®: A Self-guided Digital Acceptance and Commitment Therapy (ACT) for Fibromyalgia

Run by Fundació Sant Joan de Déu · NCT05962437 · Data updated 2026-11-12

A smartphone app (STANZA-Spain) plus standard care is being tested to see if it helps adults with fibromyalgia manage symptoms more effectively than a symptom-tracking app or standard care alone.

Quick facts

Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment360 (estimated)
SponsorFundació Sant Joan de Déu
Academic / other
Locations2 sites (Barcelona, Barcelona and 1 other locations)
StatusRecruiting
StartedJanuary 1, 2024
Main results expectedMarch 31, 2027
Study endsMarch 31, 2027
Registry record updatedJuly 23, 2026
Trial IDNCT05962437 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with fibromyalgia (ACR 2016 criteria), FIQR 35–80 at baseline, smartphone ownership, Spanish language proficiency, and stable pain treatment.

Probably not a fit

Patients not experiencing improvement or those who cannot use a smartphone or adhere to digital interventions may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a six‑month, three‑arm randomized trial enrolling adults with fibromyalgia to compare TAU alone, TAU plus the STANZA-Spain ACT-based app, and TAU plus a FibroST symptom-tracking app. The study will assess clinical outcomes, inflammatory biomarkers, and cost-utility from both healthcare and societal perspectives. Participants will be recruited at multiple hospitals in Spain and must own a compatible smartphone and speak Spanish. An embedded biomarker sub-study will evaluate potential predictors of response and will involve a subset of participants. The trial is led by Fundació Sant Joan de Déu with collaborators and aims to clarify whether digital ACT can add value to standard fibromyalgia care.

Why it matters

Potential benefit: If successful, the intervention could provide a scalable, digital option to improve symptoms and quality of life for people with fibromyalgia.

How similar studies have gone: Digital ACT and app-based interventions have shown promise in fibromyalgia and other chronic pain conditions, but results vary by design and population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Fibromyalgia diagnosis according to the 2016 ACR criteria
* Fibromyalgia Impact Questionnaire Revised (FIQR) total score within the range of 35-80 at baseline.
* Willing to maintain their current pain treatment throughout the study.
* Having a smartphone (iOS 12 or higher or Android OS 8 or higher).
* Proficient understanding of Spanish.

Exclusion Criteria:

* Presence of cognitive impairment according to clinical records.
* Diagnosis of severe medical or mental disorders such as cancer, psychotic disorder, and drug abuse according to medical records.
* Patients at risk of suicide.
* Being pregnant or planning a pregnancy during the study period, or currently breastfeeding.
* Participation in other clinical trials during the study or within the previous 12 months.
* Unable to use a smartphone.

Exclusion criteria for biomarkers substudy (30-50 patients in each study arm):

* Male sex
* Comorbid rheumatologic disorders such as lupus or severe organ dysfunction.
* History of fever (\> 38ºC) or infection within the last 2 weeks.
* Vaccination within the last 4 weeks.
* Recent physical trauma
* Needle phobia.
* Consumption of more than 8 units of caffeine per day.
* Smoking more than 5 cigarettes per day.
* Current use of oral or topical corticosteroids.
* Current use of anti-cytokine biologic medications.
* Current use of oral contraceptives.

Where it's running

  • Parc Sanitari Sant Joan de Déu (PSSJD)
    Sant Boi de Llobregat, Barcelona, Spain
    Recruiting
  • Hospital Vall d'Hebrón
    Barcelona, Barcelona, Spain
    Not yet recruiting

Study contacts

  • Principal investigator: Juan V Luciano, PhD — Universitat Autònoma de Barcelona (UAB) & FSJD
  • Study coordinator: Jaime Navarrete, PhD
  • Email: jaime.navarrete@sjd.es
  • Phone: +34936406350

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.